Internal Server Error

About Sofinnova Investments

Sofinnova Investments is a venture capital firm founded in 1974. It is primarily based out of Menlo Park, United States. As of Oct 2026, Sofinnova Investments is an active investor, having invested in 167 companies, with 5 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series E round of STAR Therapeutics Overall, Sofinnova Investments portfolio has seen 33 IPOs and 74 acquisitions including key companies like Natera, RayzeBio and Spark Therapeutics. A lot of funds co-invest with Sofinnova Investments, with names like RA Capital Management sharing a substantial percentage of its portfolio. Sofinnova Investments has team of 33 people including 9 partners.
Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 8 more
Portfolio Soonicorns
Deals in last 12 months

Sofinnova Investments' List of Top Investments

Sofinnova Investments has a portfolio of 167 companies. Their most notable investments are in Aeovian Pharmaceuticals and InCarda Therapeutics.Their portfolio spans across United States, France, United Kingdom and 11 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 20 other sectors, across stages such as Series A, Series B  and 8 more. Here is the list of top investments by Sofinnova Investments:
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.

Key facts about Natera

Key facts about RayzeBio

Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.

Key facts about Spark Therapeutics

  • Founded Year: 2013
  • Location: Philadelphia (United States)
  • Annual Revenue: $50M - $100M as on Dec 31, 2018
  • Last Known Valuation: $*****
  • Stage: Acquired
  • Total Funding till date: $82.8M
  • Employee Count: 277 as on Aug 31, 2026
  • Investors: Brookside Capital, T. Rowe Price and 6 Others
  • Latest Funding Round: Series B, May 23, 2014, $*****
  • Highlight: Acquired
myTomorrows offers a platform for early drug access to patients and doctors. The platform connects patients, doctors, and drug companies. It provides information on medical conditions, related clinical trials, and early access programs through its platform. The platform facilitates requests for drugs in development and supplies diagnostic tests.

Key facts about myTomorrows

  • Founded Year: 2012
  • Location: Amsterdam (Netherlands)
  • Stage: Series C
  • Total Funding till date: $51.3M
  • Employee Count: 154 as on Sep 30, 2026
  • Investors: Kreos Capital, EQT and 5 Others
  • Latest Funding Round: Series C, Nov 11, 2025, $*****
  • Highlight: Editors' Pick
Developer of therapeutic solutions for the treatment of immunological and inflammatory diseases. The company has an atacicept novel biologic drug that is a human recombinant fusion protein that helps in treating IgA nephropathy which is a rare autoimmune disease. It contains a soluble TACI receptor that binds to the cytokines BLyS and APRIL to promote B-cell survival and autoantibody production for the treatment of autoimmune diseases.

Key facts about Vera Therapeutics

Sofinnova Investments' Investments by Stage

Sofinnova Investments has made 61 investments in Series A stage with an average round size of $42.9M, 42 investments in Series B stage with an average round size of $57M and 24 investments in Series C stage with an average round size of $60.4M.
Here are Sofinnova Investments' investments by stage:
Stage of entry
No. of Investments
Series A
61
Series B
42
Series C
24
Series D
9
Seed
3
Others
8
Breakdown of Sofinnova Investments' investments by stage of entrySeries A (61)Series B (42)
Note: We have considered here, only first round of investments

Sofinnova Investments' Investments by Sector

Sofinnova Investments has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, Sustainability Tech and Telecom. Notably, it has invested in 139 Tech companies, 122 Enterprise (B2B) companies, 38 Software companies and at least 16 companies focusing on Consumer (B2C).
Here are Sofinnova Investments' investments by sector:
Sector
No. of Investments
Life Sciences
109
Enterprise Applications
19
High Tech
19
Sustainability Tech
12
Telecom
9
Others
46
Breakdown of Sofinnova Investments' investments by sectorsLife Sciences (109)Enterprise Applic... (19)
Note: We have considered here, only first round of investments

Sofinnova Investments' Investments by Geography

Sofinnova Investments has made most investments in United States (113), followed by France where it has made 9 investments.
Here are Sofinnova Investments' investments by geography:
Country
No. of Investments
United States
113
France
9
United Kingdom
5
Belgium
4
Denmark
4
Others
11
Breakdown of Sofinnova Investments' investments by countriesUnited States (113)France (9)
Note: We have considered here, only first round of investments

Sofinnova Investments' recent investments

Sofinnova Investments has made 7 investments in 2026 so far. STAR Therapeutics and Lisata are the latest among them.
Here are the most recent investments by Sofinnova Investments:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Oct 23, 2026
United States
Series E
3091
  [+9]
Sep 18, 2026
United States
Post IPO
3207
Aug 05, 2026
United States
Series B
6504
Jul 28, 2026
United States
Series B
9689
Jun 08, 2026
United States
Series B
6168

IPOs and Publicly Listed companies in Sofinnova Investments' Portfolio

33 of Sofinnova Investments' portfolio companies have become public. City Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2026 at marketcap of $931M and Seaport Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $912M.
Here are Sofinnova Investments' portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Oct 16, 2026
Jun 08, 2026
Series B
1281
May 01, 2026
Apr 09, 2024
Series A
1353
Mar 21, 2025
Jan 08, 2021
Series B
5992
Sep 26, 2024
Feb 13, 2024
Series D
4620
Jun 07, 2024
Aug 23, 2023
Series B
3228

Acquired companies in Sofinnova Investments' Portfolio

74 companies from Sofinnova Investments' portfolio have been acquired. The most recent acquisition was Marea Therapeutics in Sep 2026 by Lisata for $*****.
Here are Sofinnova Investments' portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Sep 18, 2026
-
-
3583
Jul 31, 2026
Jun 05, 2023
Series B
9675
Mar 31, 2026
Aug 14, 2017
Series E
1093
Jan 21, 2026
Sep 18, 2026
Post IPO
5844
Dec 12, 2025
Aug 26, 2015
Series C
6705

Team profile of Sofinnova Investments

Sofinnova Investments has a team of 33 members including 9 Partners and 1 Principal located in United States, France and 3 more locations. Sofinnova Investments' team does not sit on the board of any company as of now.
Here is a list of top team members in Sofinnova Investments:
Name
Designation
Location
Board Memberships
Contact Details
Partner
Munich
-
-
Partner
San Francisco
-
-
Partner
Menlo Park
-
-
Partner
San Francisco
-
-
Partner
New York City
-
-
Partner
Ottawa
-
-
Partner
Paris
-
-
Partner
Paris
-
Partner
Los Angeles
-
-

Co-investors of Sofinnova Investments

Over the past 28 years, 836 investors have co-invested in Sofinnova Investments's portfolio companies. This includes funds and angels.

  • Invested before Sofinnova Investments: HHS, Novo Holdings and 224 others have invested in rounds before Sofinnova Investments. There are 8 companies where HHS has invested before Sofinnova Investments and 8 companies where Novo Holdings has invested before Sofinnova Investments.
  • Top Co-investors of Sofinnova Investments: 308 investors entered a company along with Sofinnova Investments. These include investors like RA Capital Management (12 companies).
  • Invested after Sofinnova Investments: A total of 302 investors have invested in Sofinnova Investments's portfolio after their investments. Top Investors include RA Capital Management (7 companies), Rock Springs Capital (7 companies) and Vivo Capital (5 companies).

Recent News related to Sofinnova Investments

•
Sofinnova Partners Closes Oversubscribed €82 Million Fund for Medtech CompaniesThe Joplin Globe•Sep 28, 2026•Sofinnova Investments
•
CT Green Chemistry Company Raises $23M to Support ExpansionHartford Business Journal•May 26, 2026•P2 Science, Sofinnova Partners, Sofinnova Investments
View all news related to Sofinnova Investments

FAQs about Sofinnova Investments

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford